|Bid||2.5000 x 4000|
|Ask||2.5100 x 4000|
|Day's Range||2.3300 - 2.5450|
|52 Week Range||2.0800 - 34.2780|
|Beta (5Y Monthly)||1.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 15, 2022 - Feb 21, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.18|
Signify (SGFY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Genetic medical testing specialist Invitae (NYSE: NVTA) didn't pass the investment test for one researcher late on Thursday. After market hours on Thursday, financial services company Piper Sandler initiated coverage of Invitae stock. "We think germline testing is becoming more commoditized and Invitae has a late start to somatic cancer," the prognosticator wrote in a research note, referring to two types of genetic screening for cancer.
The genetic testing company has been unprofitable as it spent heavily (but that's only part of the story).